预防性皮下注射丁溴东莨菪碱对临终患者死亡咆哮的影响:SILENCE随机临床试验
这项多中心随机双盲安慰剂对照试验在荷兰6家临终关怀机构纳入162例预期寿命≥3天的临终患者,比较预防性皮下注射丁溴东莨菪碱20mg每日四次与安慰剂对死亡咆哮的影响。
要点
- 预防性丁溴东莨菪碱使死亡咆哮发生率从27%降至13%。
- 48小时累积发生率丁溴东莨菪碱组8% vs 安慰剂组17%。
- 不良事件包括躁动、口干和尿潴留,组间差异未报告统计学意义。
核心结论
- 在临终患者中,预防性皮下注射丁溴东莨菪碱较安慰剂显著降低死亡咆哮的发生。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,在荷兰6家临终关怀机构进行。
- 229例提供预先知情同意,最终162例随机分配,157例纳入主要分析。
- 干预为皮下注射丁溴东莨菪碱20mg每日四次(n=79)或安慰剂(n=78)。
- 主要结局为连续两个时间点(间隔4小时)出现Back分级≥2级的死亡咆哮。
主要发现
- 48小时累积发生率丁溴东莨菪碱组8%,安慰剂组17%。
- 躁动发生率丁溴东莨菪碱组28%(22/79)vs 安慰剂组23%(18/78)。
- 口干发生率10%(8/79)vs 15%(12/78),尿潴留发生率23%(6/26)vs 17%(3/18)。
关键数值与推荐
- 死亡咆哮定义为Back分级≥2级(0-3级,3级为站在门口可闻及)。
- 主要结局需在间隔4小时的连续两个时间点评估。
临床怎么用
- 对预期寿命≥3天的临终患者,可考虑预防性使用皮下丁溴东莨菪碱20mg每日四次以减少死亡咆哮。
- 用药期间需监测躁动、口干和尿潴留等抗胆碱能不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Death rattle, defined as noisy breathing caused by the presence of mucus in the respiratory tract, is relatively common among dying patients. Although clinical guidelines recommend anticholinergic drugs to reduce the death rattle after nonpharmacological measures fail, evidence regarding their efficacy is lacking. Given that anticholinergics only decrease mucus production, it is unknown whether prophylactic application may be more appropriate. OBJECTIVE: To determine whether administration of prophylactic scopolamine butylbromide reduces the death rattle. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized, double-blind, placebo-controlled trial was performed in 6 hospices in the Netherlands. Patients with a life expectancy of 3 or more days who were admitted to the participating hospices were asked to give advance informed consent from April 10, 2017, through December 31, 2019. When the dying phase was recognized, patients fulfilling the eligibility criteria were randomized. Of the 229 patients who provided advance informed consent, 162 were ultimately randomized. The date of final follow-up was January 31, 2020. INTERVENTIONS: Administration of subcutaneous scopolamine butylbromide, 20 mg four times a day (n = 79), or placebo (n = 78). MAIN OUTCOMES AND MEASURES: The primary outcome was the occurrence of a grade 2 or higher death rattle as defined by Back (range, 0-3; 0, no rattle; 3, rattle audible standing in the door opening) measured at 2 consecutive time points with a 4-hour interval. Secondary outcomes included the time between recognizing the dying phase and the onset of a death rattle and anticholinergic adverse events. RESULTS: Among 162 patients who were randomized, 157 patients (97%; median age, 76 years [IQR, 66-84 years]; 56% women) were included in the primary analyses. A death rattle occurred in 10 patients (13%) in the scopolamine group compared with 21 patients (27%) in the placebo group (difference, 14%; 95% CI, 2%-27%, P = .02). Regarding secondary outcomes, an analysis of the time to death rattle yielded a subdistribution hazard ratio (HR) of 0.44 (95% CI, 0.20-0.92; P = .03; cumulative incidence at 48 hours: 8% in the scopolamine group vs 17% in the placebo group). In the scopolamine vs placebo groups, restlessness occurred in 22 of 79 patients (28%) vs 18 of 78 (23%), dry mouth in 8 of 79 (10%) vs 12 of 78 (15%), and urinary retention in 6 of 26 (23%) vs 3 of 18 (17%), respectively. CONCLUSIONS AND RELEVANCE: Among patients near the end of life, prophylactic subcutaneous scopolamine butylbromide, compared with placebo, significantly reduced the occurrence of the death rattle. TRIAL REGISTRATION: trialregister.nl Identifier: NTR6264.
引用
- van Esch HJ, van Zuylen L, Geijteman ECT, et al. Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life: The SILENCE Randomized Clinical Trial. JAMA. 2021. PMID: 34609452. doi:10.1001/jama.2021.14785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。